Yeah, missiles were being launched into Israel every day and shareholders were bitching and moaning about the quarterly filing being late. It is hard for me to comprehend the level of complete and utter disregard some folks have for others in what was a literal war zone at the time. Screw the goal of trying to protect one's family with missiles flying... let's get to the office and get those financials reviewed so our damn shareholders won't be upset with being late in reporting.
And yes, our CEO is constantly pressured to provide dates to impatient shareholders who bitch if no dates are given, and bitch if dates are given but have to be adjusted. All this from a small company with 14 employees (according to LinkedIn) who are advancing their cutting edge products on multiple fronts. Investors are upset because the phase 2 interim data has been pushed out another few weeks. The reasons have been explained in detail in interviews, presentations, and Twitter responses. But investors want that data and want it now. Otherwise, it's time for doubts that the data may not be that good. Bitch if the data gets pushed out, and bitch if the data is presented on the original schedule and is rejected by regulators because the company didn't take the time to properly set up biomarker endpoints that emerged during the conduct of the trial or take into account events that transpired since the original data release date. No investor would forgive the CEO for screwing that up. It's a no-win scenario for Todos employees.
Perhaps I just woke up in a foul mood, but in reading investors comments on multiple sites, I'm ready to start suggesting investors who can't handle the delays and understand all that's going on within this little company should sell their shares and invest in Pfizer. I'm sure that with their thousands of employees they meet all of their deadlines, and investors won't have anything to complain about regarding timelines and expectations.
I don't give a crap about expected deadlines being missed if the reasons are valid and honest. I have no reason to believe Gerald has been anything but honest and forthcoming with shareholders. This is one of the most transparent OTC companies you will find, and they appear to have done their due diligence in the regulatory space they will be addressing with their data. However, with former AMBS investors who lost money grinding their axe against Gerald here daily, it's easy to get all caught up in missed expectations and start to question motives when dates are extended or revised. Why would anyone remain invested in a company where they believe the CEO is deceiving shareholders?
Investors should be confident in what they own, and not let naysayers with personal agendas against the CEO shake their confidence. If a shareholder is having doubts, I suggest they sell and move on. Or at least spend some time revisiting recent conference calls and presentations to try to understand all that's going on in this tiny little company trying to compete against the likes of Pfizer and Merck. And for those who believe delays are causing us to miss the boat... you're clearly not staying informed. Covid is NOT going away. I'd rather the company take the time to get it right with Tollovir than rush the trials and data analysis and get it wrong. Getting it right will greatly benefit shareholders.
